This text is a result of machine translation.
Suspension of large amount subscription of Jingshun great wall reform opportunity hybrid fund
Gaoshanwen: the valuation level of a shares is not high. China will maintain a long-term economic growth level of 4.5%
Yi Ming ang Ke delivers a statement to the main board of the Hong Kong stock exchange to develop a new generation of tumor immunotherapy
National Development and Reform Commission: revise and expand the catalogue of industries encouraging foreign investment and timely launch a new batch of major foreign-funded projects
360 DigiTech: A Leader in an Oscillating Market
360 DigiTech's core competencies of asset-light model and technology focus offer a bright future. In the first quarter of 2022, the firm outperformed its competitors in terms of user amount, total loans granted and revenue. However, it operates in a market that has been performing below expectations as risks mount and profitability decreases.
Jun 25, 2022 10:00 AM
Many banks have issued documents to stop the intelligent investment advisory business. Insiders: it may be restarted after the regulatory rules are released
BeiGene: a Vast Opportunity Lies Ahead – But We Remain Cautious
BeiGene, a leader in China's novel pharmaceutical industry, recently received approval in Kuwait, Bahrain, and Qatar for its medication BRUKINSA (zanubrutinib). Previous contracts with major biopharma have produced substantial licensing income, but they did not lessen BeiGene's financial burden.
Jun 24, 2022 12:13 PM
UBS wealth management: the profit outlook of Asian stock markets is resilient
Huchunhua: further strengthen trade and investment cooperation and push China France practical cooperation to a higher level